Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 2,517 Shares

Key Points

• Adam Laponis, CFO of Twist Bioscience, sold 2,517 shares at an average price of $32.92, totaling approximately $82,860, reducing his ownership to 91,525 shares, worth about $3 million.
• Twist Bioscience's stock experienced a 2.2% decline, trading at $31.19, amid significant trading volume of 2,506,977 shares.
• Analysts have mixed ratings for TWST, with the consensus rating being a "Moderate Buy" and an average price target of $48.50 based on recent adjustments from various research firms.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 2,517 shares of Twist Bioscience stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $32.92, for a total transaction of $82,859.64. Following the transaction, the chief financial officer directly owned 91,525 shares in the company, valued at approximately $3,013,003. This represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Adam Laponis also recently made the following trade(s):

• On Wednesday, October 8th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The stock was sold at an average price of $31.15, for a total transaction of $93,450.00.
• On Monday, October 6th, Adam Laponis sold 5,875 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total transaction of $189,116.25.

Twist Bioscience Stock Down 2.2%

TWST traded down $0.70 during trading on Friday, hitting $31.19. The company had a trading volume of 2,506,977 shares, compared to its average volume of 1,280,806. The company has a market capitalization of $1.88 billion, a PE ratio of -21.51 and a beta of 2.38. Twist Bioscience Corporation has a one year low of $24.07 and a one year high of $55.33. The firm's 50-day moving average price is $27.68 and its 200 day moving average price is $32.75. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The firm had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on TWST. Cowen restated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Twist Bioscience in a research note on Wednesday. Evercore ISI decreased their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research note on Tuesday. Finally, Barclays decreased their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research note on Thursday, October 2nd. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $48.50.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC lifted its holdings in shares of Twist Bioscience by 2.5% during the 2nd quarter. ARK Investment Management LLC now owns 6,400,441 shares of the company's stock worth $235,472,000 after acquiring an additional 158,846 shares during the period. Vanguard Group Inc. increased its position in Twist Bioscience by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock worth $230,356,000 after purchasing an additional 60,276 shares in the last quarter. William Blair Investment Management LLC increased its position in Twist Bioscience by 2.6% during the 2nd quarter. William Blair Investment Management LLC now owns 3,906,604 shares of the company's stock worth $143,724,000 after purchasing an additional 99,737 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Twist Bioscience by 186.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after purchasing an additional 1,588,587 shares in the last quarter. Finally, EdgePoint Investment Group Inc. increased its position in Twist Bioscience by 114.3% during the 2nd quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company's stock worth $87,779,000 after purchasing an additional 1,272,732 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.